Fertram Sigurjonsson, Founder and CEO of Medical-Fish-Skin Company Kerecis, Receives the EWMA President’s Wound Care Entrepreneur of the Year Award
Monday, 4 September 2023 at 14.00 “ 15.00 CESTIn connection with the completion of the acquisition of Kerecis, Coloplast will host a conference call with Fertram Sigurjonsson, Founder and CEO of...
Coloplast has signed an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for up to USD 1.3 billion (around DKK 8.9 billion), of which USD 1.2...
ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis, the company pioneering the use of fish skin and fatty acids in cellular therapy, tissue regeneration and protection, today announced that Fertram Sigurjonsson, Kerecis Founder and CEO, and Mike Cadigan, Chief Financial Officer, will participate in meetings at SVB Leerink Annual Global Healthcare Conference on Monday and Tuesday, February 14 and 15, 2022.
ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)-- Kerecis®, the company pioneering the use of fish skin and fatty acids in cellular therapy, tissue regeneration and protection, has received authorization from the FDA to market Kerecis Omega3 SurgiBind™. The product, which is available now in the U.S., is an implantable fish-skin graft for use in plastic and reconstructive surgery. The product is indicated for implantation to reinforce soft tissue where weakness exists, in patients requiring soft tissue repair, or reinforcement in plastic or reconstructive surgery.